Cogent Biosciences Inc

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Series A Non-Voting Convertible · Additional · Accumulated · Total
Preferred Stock · Common Stock · Paid-in · Other Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Shares	Amount	Capital	(Income) Loss	Deficit	Equity
Balance at December 31, 2020	132,244	$110,881	32,347,905	$32	$322,454	$—	$(198,700)	$234,667
Conversion of Series A non-voting preferred stock into common stock	(28,955)	(25,481)	7,238,750	8	25,473	—	—	—
Issuance of common stock for services	—	—	31,683	—	260	—	—	260
Issuance of common stock upon exercise of stock options	—	—	15,758	—	24	—	—	24
Issuance of common stock under Employee Stock Purchase Plan	—	—	4,497	—	31	—	—	31
Issuance of common stock under ATM, net of issuance costs of $1.2 million	—	—	3,954,900	4	38,002	—	—	38,006
Issuance of common stock to settle CVR liability	—	—	212,429	—	2,043	—	—	2,043
Stock-based compensation expense	—	—	—	—	11,426	—	—	11,426
Net loss	—	—	—	—	—	—	(72,273)	(72,273)
Balances at December 31, 2021	103,289	$85,400	43,805,922	$44	$399,713	$—	$(270,973)	$214,184
Issuance of common stock in underwritten public offering, net of offering costs of $10.8 million	—	—	17,899,698	18	161,897	—	—	161,915
Pre-funded warrant exercise	—	—	2,424,242	2	22	—	—	24
Conversion of Series A non-voting preferred stock into common stock	(22,239)	(19,570)	5,559,750	6	19,564	—	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	49,000	—	351	—	—	351
Issuance of common stock from exercises	—	—	154,822	—	1,238	—	—	1,238
Unrealized losses on marketable securities	—	—	—	—	—	(104)	—	(104)
Stock-based compensation expense	—	—	—	—	18,368	—	—	18,368
Net loss	—	—	—	—	—	—	(140,241)	(140,241)
Balances at December 31, 2022	81,050	$65,830	69,893,434	$70	$601,153	$(104)	$(411,214)	$255,735
Issuance of common stock in underwritten public offering, net of offering costs of $10.7 million	—	—	14,375,000	14	161,775	—	—	161,789
Conversion of Series A non-voting preferred stock into common stock	(6,585)	(5,795)	1,646,250	2	5,793	—	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	85,878	—	752	—	—	752
Issuance of common stock from exercises	—	—	123,687	—	965	—	—	965
Unrealized gains on marketable securities	—	—	—	—	—	350	—	350
Stock-based compensation expense	—	—	—	—	30,621	—	—	30,621
Net loss	—	—	—	—	—	—	(192,410)	(192,410)
Balances at December 31, 2023	74,465	$60,035	86,124,249	$86	$801,059	$246	$(603,624)	$257,802

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.